Literature DB >> 10913807

Estimating significance level and power comparisons for testing multiple endpoints in clinical trials.

J Gong1, J C Pinheiro, D L DeMets.   

Abstract

Clinical trials generally include several outcome measures of interest for assessing treatment efficacy and harm. Traditionally a single measure, the primary outcome, is selected and used as the basis for the design, including sample size and power. Secondary outcomes are then generally ordered with respect to their clinical relevance and importance. While this has become the traditional paradigm, recent trials have suggested the need for additional approaches. In this setting, two outcomes are viewed as key, either one being sufficient for proof of efficacy, but with an ordering of preference. The basic question, in such cases, is how to control the overall significance level for the trial. We describe and compare two methods for testing primary and secondary endpoints, accounting for their hierarchical nature-the ordering preference. Both methods are sequential, in the sense that the secondary endpoint is only tested when the primary outcome fails to reach significance. The first method uses a global test for the combination of the primary and secondary endpoints, while the second uses a partial Bonferroni correction. Simulation results indicate that the Bonferroni adjustment method performs as well as the global test method in most cases, and even better in some cases.

Mesh:

Year:  2000        PMID: 10913807     DOI: 10.1016/s0197-2456(00)00049-0

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  5 in total

1.  Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.

Authors:  Yuki Ando; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Tomoyuki Sugimoto; Takashi Sozu; Yuko Ohno
Journal:  Stat Biopharm Res       Date:  2015-06-24       Impact factor: 1.452

2.  Impact of early cART in the gut during acute HIV infection.

Authors:  Claire Deleage; Alexandra Schuetz; W Gregory Alvord; Leslie Johnston; Xing-Pei Hao; David R Morcock; Rungsun Rerknimitr; James L K Fletcher; Suwanna Puttamaswin; Nittaya Phanuphak; Robin Dewar; Joseph M McCune; Irini Sereti; Merlin Robb; Jerome H Kim; Timothy W Schacker; Peter Hunt; Jeffrey D Lifson; Jintanat Ananworanich; Jacob D Estes
Journal:  JCI Insight       Date:  2016-07-07

3.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

4.  Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse.

Authors:  Blazej Misiak; Dorota Frydecka; Ryszard Slezak; Patryk Piotrowski; Andrzej Kiejna
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

5.  Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.

Authors:  Martina E McMenamin; Jessica K Barrett; Anna Berglind; James M S Wason
Journal:  Stat Med       Date:  2022-02-23       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.